Glinvika Tablet ER is a combination oral antidiabetic medication containing Gliclazide 80 mg and Metformin 500 mg, formulated for extended-release to provide sustained glycemic control in patients with type 2 diabetes mellitus. Gliclazide, a sulfonylurea derivative, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose utilization. The extended-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glinvika Tablet ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or lifestyle modifications alone. It should be used with caution in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. Regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia and lactic acidosis is essential during therapy. This combination therapy offers a complementary mechanism of action, optimizing glycemic management in type 2 diabetes while reducing the risk of complications associated with poor glycemic control.